drugset / Trial / NCT07283900
Ascorbate in Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.
Timeline
- Start
- 2026-03-11
- Primary completion
- 2028-05-01
- Completion
- 2029-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Vitamin C | Other / unclassified | 75 g | Intravenous |